From the Journals

AML leads percent gains in 5-year survival among leukemias


 

Over the 60-year span from the early 1950s to 2013, the 5-year survival rate for all leukemias increased by 500%, according to data from the Surveillance, Epidemiology, and End Results Program.

For 2008-2013, the 5-year relative survival rate for all leukemias was 60.1%, compared with 10% during 1950-1954, said Ali H. Mokdad, PhD, and his associates at the Institute for Health Metrics and Evaluation at the University of Washington, Seattle (JAMA 2017;317[4]:388-406).

Five-year survival rate for all leukenia up 500%
Data for the various types of leukemia were not available for 1950-1954, so the changes in the 5-year survival for those included in the study are calculated from 1973-1977 to 2008-2013. Chronic lymphoid leukemia (CLL) had the highest survival rate at both time periods and the smallest increase at 23%. Acute lymphoid leukemia (ALL) had a 74% increase in survival, chronic myeloid leukemia (CML) had a 215% increase in survival, and acute myeloid leukemia (AML) had the largest increase at 342%, the investigators reported.

Recommended Reading

CAR T-cell therapy eyed for CLL patients with residual disease
B-Cell Lymphoma ICYMI
CLL: Genetic aberrations predict poor treatment response in elderly
B-Cell Lymphoma ICYMI
Survival in CLL predicted by minimum residual disease
B-Cell Lymphoma ICYMI
CD49d trumps novel recurrent mutations for predicting overall survival in CLL
B-Cell Lymphoma ICYMI
Minimal residual disease status predicts 10-year survival in CLL
B-Cell Lymphoma ICYMI
Targeted therapies predicted to blow out costs for CLL
B-Cell Lymphoma ICYMI
Idelalisib held unlikely to become frontline therapy for CLL
B-Cell Lymphoma ICYMI
Lenalidomide improves PFS after 1st and 2nd line CLL therapy
B-Cell Lymphoma ICYMI
Ibrutinib continues to wow in CLL/SLL
B-Cell Lymphoma ICYMI
Lenalidomide maintenance extended progression-free survival in high-risk CLL
B-Cell Lymphoma ICYMI